SCHEMBL5908033

SCHEMBL5908033

CC(C)(C)NC[C@H](O)COc1nsnc1Cl

nearest known ligand 0.58

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 3/20 0.58
ADRB2 P07550 3/20 0.58
ADRB1 P08588 3/20 0.58
ADRB3 P13945 3/20 0.58
CYP1A2 P05177 1/20 0.58
CYP3A4 P08684 1/20 0.58
HTR1A P08908 1/20 0.58
NFKB1 P19838 1/20 0.58
DRD1 P21728 1/20 0.58
SIGMAR1 Q99720 1/20 0.58
TDP1 Q9NUW8 1/20 0.58
SMN1; SMN2 Q16637 1/20 0.50
BLM P54132 1/20 0.50
KMT2A Q03164 2/20 0.46
MEN1 O00255 1/20 0.46
HTT P42858 1/20 0.46
MAPT P10636 2/20 0.45
GLA P06280 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1587431 1.00 CYP2D6 (0.58) CYP2D6ADRB2ADRB1ADRB3CYP1A2
Hydrochloric Acid SCHEMBL9333736 0.99 CYP2D6 (0.57) CYP2D6ADRB2ADRB1ADRB3CYP1A2
SCHEMBL11412068 0.84 CYP2D6 (0.59) CYP2D6ADRB2ADRB1ADRB3CYP1A2
SCHEMBL11403829 0.84 CYP2D6 (0.59) CYP2D6ADRB2ADRB1ADRB3CYP1A2
SCHEMBL11758160 0.84 CYP2D6 (0.59) CYP2D6ADRB2ADRB1ADRB3CYP1A2
SCHEMBL11403374 0.84 CYP2D6 (0.59) CYP2D6ADRB2ADRB1ADRB3CYP1A2
Hydrochloric Acid SCHEMBL11407352 0.83 CYP2D6 (0.58) CYP2D6ADRB2ADRB1ADRB3CYP1A2
Hydrochloric Acid SCHEMBL11412217 0.83 CYP2D6 (0.58) CYP2D6ADRB2ADRB1ADRB3CYP1A2
Hydrochloric Acid SCHEMBL11406447 0.83 CYP2D6 (0.58) CYP2D6ADRB2ADRB1ADRB3CYP1A2
SCHEMBL11753865 0.82 CYP2D6 (0.57) CYP2D6ADRB2ADRB1ADRB3CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060258652-A1 Beta-blockers having antioxidant and no-donor activity YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) 2006-11-16 US disclosed
WO-2004047837-A2 BETA-BLOCKERS HAVING ANTIOXIDANT AND NITRIC OXIDE-DONOR ACTIVITY YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) 2004-06-10 WO disclosed
US-4031125-A 3-Sulfonate ester of 2,3-dihydroxypropylamine MERCK & CO., INC. (US) 1977-06-21 US disclosed
US-3962338-A Novel methods and compounds employed therein MERCK & CO., INC. (US) 1976-06-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060258652-A1 Beta-blockers having antioxidant and no-donor activity ADRB1, ADRB2, ADRB3 CYP2D6 699/4885ADRB2 2/4885ADRB1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.